Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder
- 1 November 2002
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 47 (5) , 785-788
- https://doi.org/10.1067/mjd.2002.126273
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLLAmerican Journal of Hematology, 2001
- Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host DiseaseAnnals of Internal Medicine, 2000
- Humoral and Cellular Autoimmunity in Autoimmune Bullous Skin DisordersInternational Archives of Allergy and Immunology, 2000
- Analysis of the T Cells that Are Potentially Involved in Autoantibody Production in Pemphigus VulgarisThe Journal of Dermatology, 1999
- Regulation of B-cell commitment to plasma cells or to memory B cellsSeminars in Immunology, 1997
- Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.Journal of Clinical Investigation, 1997
- Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted with lymphocytes from patients.Journal of Clinical Investigation, 1993
- Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic.Journal of Clinical Investigation, 1992
- Induction of Pemphigus in Neonatal Mice by Passive Transfer of IgG from Patients with the DiseaseNew England Journal of Medicine, 1982
- Neonatal pemphigus vulgaris: role of passively transferred pemphigus antibodiesBritish Journal of Dermatology, 1982